Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis

Area of Science:

• Oncology
• Natural Products Chemistry
• Molecular Biology

Background:

• Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide.
• Metastasis is a major challenge in CRC treatment, necessitating novel therapeutic strategies.
• Natural products offer a promising avenue for developing new anti-cancer agents.

Purpose of the Study:

• To investigate the anti-cancer effects of Withaferin-A (WA) on colorectal cancer (CRC) cells.
• To elucidate the molecular mechanisms underlying WA's inhibition of CRC growth and metastasis.
• To evaluate WA's potential as a therapeutic agent for CRC.

Main Methods:

• In vitro studies using CRC cell lines (HCT116, SW480) with assays for viability, proliferation, migration, and invasion.
• In vivo evaluation using xenograft and metastasis mouse models to assess tumor growth and toxicity.
• Molecular analyses including transcriptome sequencing, qRT-PCR, Western blot, and immunoprecipitation to identify key molecular targets and pathways.

Main Results:

• WA significantly suppressed the growth, migration, and invasion of CRC cells.
• Transcriptome analysis revealed that WA inhibits epithelial-mesenchymal transition (EMT), Heat Shock Protein 90 (HSP90), and Hypoxia-inducible factor 1-alpha (HIF-1α) in CRC.
• WA directly inhibited HSP90 and HIF-1α, disrupting their interaction and downstream signaling, thereby reducing CRC metastasis.

Conclusions:

• WA effectively inhibits CRC growth, migration, and invasion by targeting the HSP90/HIF-1α/EMT axis.
• The findings support WA's potential as a novel therapeutic agent for colorectal cancer.
• Further research into WA's mechanism and clinical efficacy is warranted for CRC treatment.